Month: February 2022

4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium

Following discontinuation of ERT, AGA activity was stable at 14-fold mean normal level through week 37 (Patient 1) and stable...

error: Content is protected !!